Last reviewed · How we verify

Vancomycin and Gentamicin

Memorial Sloan Kettering Cancer Center · FDA-approved active Small molecule

Vancomycin and gentamicin are a combination antibiotic regimen that inhibits bacterial cell wall synthesis and protein synthesis to treat serious infections.

Vancomycin and gentamicin are a combination antibiotic regimen that inhibits bacterial cell wall synthesis and protein synthesis to treat serious infections. Used for Empiric treatment of febrile neutropenia in cancer patients, Serious gram-positive and gram-negative bacterial infections in immunocompromised hosts.

At a glance

Generic nameVancomycin and Gentamicin
SponsorMemorial Sloan Kettering Cancer Center
Drug classAntibiotic combination (glycopeptide + aminoglycoside)
TargetBacterial cell wall (vancomycin) and bacterial 30S ribosome (gentamicin)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall peptidoglycan cross-linking, primarily effective against gram-positive organisms. Gentamicin is an aminoglycoside that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. This combination is used empirically for synergistic coverage of serious infections, particularly in immunocompromised patients such as those with cancer.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: